124 related articles for article (PubMed ID: 37997910)
21. Quality of life of patients after retropubic prostatectomy - pre- and postoperative scores of the EORTC QLQ-C30 and QLQ-PR25.
Bach P; Döring T; Gesenberg A; Möhring C; Goepel M
Health Qual Life Outcomes; 2011 Nov; 9():93. PubMed ID: 22047686
[TBL] [Abstract][Full Text] [Related]
22. Racial and Ethnic Disparities in Prostate Cancer Outcomes in the Veterans Affairs Health Care System.
Yamoah K; Lee KM; Awasthi S; Alba PR; Perez C; Anglin-Foote TR; Robison B; Gao A; DuVall SL; Katsoulakis E; Wong YN; Markt SC; Rose BS; Burri R; Wang C; Aboiralor O; Fink AK; Nickols NG; Lynch JA; Garraway IP
JAMA Netw Open; 2022 Jan; 5(1):e2144027. PubMed ID: 35040965
[TBL] [Abstract][Full Text] [Related]
23. Modified the 8th AJCC staging system for patients with advanced prostate cancer: a study based on SEER database.
Sun C; Yang D; Zhu J; Zhou Y; Xiang C; Wu S
BMC Urol; 2022 Nov; 22(1):185. PubMed ID: 36384495
[TBL] [Abstract][Full Text] [Related]
24. Examining relationships between age at diagnosis and health-related quality of life outcomes in prostate cancer survivors.
Kurian CJ; Leader AE; Thong MSY; Keith SW; Zeigler-Johnson CM
BMC Public Health; 2018 Aug; 18(1):1060. PubMed ID: 30139347
[TBL] [Abstract][Full Text] [Related]
25. Patients' education level and treatment modality for prostate cancer in the Finnish Randomized Study of Screening for Prostate Cancer.
Kilpeläinen TP; Talala K; Taari K; Raitanen J; Kujala P; Pylväläinen J; Tammela TL; Auvinen A
Eur J Cancer; 2020 May; 130():204-210. PubMed ID: 32229417
[TBL] [Abstract][Full Text] [Related]
26. Impact of Relugolix Versus Leuprolide on the Quality of Life of Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study.
Tombal B; Collins S; Morgans AK; Hunsche E; Brown B; Zhu E; Bossi A; Shore N
Eur Urol; 2023 Dec; 84(6):579-587. PubMed ID: 37833178
[TBL] [Abstract][Full Text] [Related]
27. Literacy, race, and PSA level among low-income men newly diagnosed with prostate cancer.
Wolf MS; Knight SJ; Lyons EA; Durazo-Arvizu R; Pickard SA; Arseven A; Arozullah A; Colella K; Ray P; Bennett CL
Urology; 2006 Jul; 68(1):89-93. PubMed ID: 16844451
[TBL] [Abstract][Full Text] [Related]
28. Correlation of serum β2-microglobulin levels with prostate-specific antigen, Gleason score, clinical stage, tumor metastasis and therapy efficacy in prostate cancer.
Zhang YX; Wang L; Ji PY; Zhao GG; Zhong GP; Wang ZP
Arch Med Res; 2013 May; 44(4):259-65. PubMed ID: 23707648
[TBL] [Abstract][Full Text] [Related]
29. Independent Validation of the American Joint Committee on Cancer 8th Edition Prostate Cancer Staging Classification.
Bhindi B; Karnes RJ; Rangel LJ; Mason RJ; Gettman MT; Frank I; Tollefson MK; Lin DW; Thompson RH; Boorjian SA
J Urol; 2017 Dec; 198(6):1286-1294. PubMed ID: 28669765
[TBL] [Abstract][Full Text] [Related]
30. Insufficient Lycopene Intake Is Associated With High Risk of Prostate Cancer: A Cross-Sectional Study From the National Health and Nutrition Examination Survey (2003-2010).
Lu Y; Edwards A; Chen Z; Tseng TS; Li M; Gonzalez GV; Zhang K
Front Public Health; 2021; 9():792572. PubMed ID: 34966715
[TBL] [Abstract][Full Text] [Related]
31. The EORTC QLQ-C30 Summary Score as Prognostic Factor for Survival of Patients with Cancer in the "Real-World": Results from the Population-Based PROFILES Registry.
Husson O; de Rooij BH; Kieffer J; Oerlemans S; Mols F; Aaronson NK; van der Graaf WTA; van de Poll-Franse LV
Oncologist; 2020 Apr; 25(4):e722-e732. PubMed ID: 32297435
[TBL] [Abstract][Full Text] [Related]
32. Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT.
Hamdy FC; Donovan JL; Lane JA; Mason M; Metcalfe C; Holding P; Wade J; Noble S; Garfield K; Young G; Davis M; Peters TJ; Turner EL; Martin RM; Oxley J; Robinson M; Staffurth J; Walsh E; Blazeby J; Bryant R; Bollina P; Catto J; Doble A; Doherty A; Gillatt D; Gnanapragasam V; Hughes O; Kockelbergh R; Kynaston H; Paul A; Paez E; Powell P; Prescott S; Rosario D; Rowe E; Neal D
Health Technol Assess; 2020 Aug; 24(37):1-176. PubMed ID: 32773013
[TBL] [Abstract][Full Text] [Related]
33. Image guided hypofractionated radiotherapy and quality of life for localized prostate cancer: prospective longitudinal study in 337 patients.
Jereczek-Fossa BA; Santoro L; Zerini D; Fodor C; Vischioni B; Dispinzieri M; Bossi-Zanetti I; Gherardi F; Bonora M; Caputo M; Vavassori A; Cambria R; Garibaldi C; Cattani F; Matei DV; Musi G; De Cobelli O; Orecchia R
J Urol; 2013 Jun; 189(6):2099-103. PubMed ID: 23313200
[TBL] [Abstract][Full Text] [Related]
34. Risk of prostate cancer in relatives of prostate cancer patients in Sweden: A nationwide cohort study.
Xu X; Kharazmi E; Tian Y; Mukama T; Sundquist K; Sundquist J; Brenner H; Fallah M
PLoS Med; 2021 Jun; 18(6):e1003616. PubMed ID: 34061847
[TBL] [Abstract][Full Text] [Related]
35. The effect of prostate cancer screening on stage IV disease in America.
Colli JL
Int Urol Nephrol; 2011 Jun; 43(2):391-6. PubMed ID: 20963490
[TBL] [Abstract][Full Text] [Related]
36. Association between literacy, compliance with prostate cancer screening, and cancer aggressiveness: results from a Brazilian screening study.
Tobias-Machado M; Carvalhal GF; Freitas CH; Reis RB; Reis LO; Nogueira L; Machado RD; Magnabosco W; Vieira RA; Mauad EC; Carvalho AL; Faria EF;
Int Braz J Urol; 2013; 39(3):328-34. PubMed ID: 23849582
[TBL] [Abstract][Full Text] [Related]
37. Targeted-cryosurgical ablation of the prostate with androgen deprivation therapy: quality of life in high-risk prostate cancer patients.
Kang SH; Kim JW; Bae JH; Park HS; Moon DG; Yoon DK; Cheon J; Kim JJ
Asian J Androl; 2006 Sep; 8(5):629-36. PubMed ID: 16847531
[TBL] [Abstract][Full Text] [Related]
38. BPH: a tell-tale sign of prostate cancer? Results from the Prostate Cancer and Environment Study (PROtEuS).
Boehm K; Valdivieso R; Meskawi M; Larcher A; Sun M; Sosa J; Blanc-Lapierre A; Weiss D; Graefen M; Saad F; Parent MÉ; Karakiewicz PI
World J Urol; 2015 Dec; 33(12):2063-9. PubMed ID: 25824539
[TBL] [Abstract][Full Text] [Related]
39. Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening.
Assel M; Dahlin A; Ulmert D; Bergh A; Stattin P; Lilja H; Vickers AJ
Eur Urol; 2018 Jun; 73(6):961-967. PubMed ID: 29066048
[TBL] [Abstract][Full Text] [Related]
40. Differences in the aggressiveness of prostate cancer among Korean, Caucasian, and African American men: A retrospective cohort study of radical prostatectomy.
Jeong IG; Dajani D; Verghese M; Hwang J; Cho YM; Hong JH; Kim CS; Ahn H; Ro JY
Urol Oncol; 2016 Jan; 34(1):3.e9-14. PubMed ID: 26345648
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
